A next-generation KRAS pill beat older ones and helped people with lung cancer live longer
In a phase 3 trial published Oct. 25, 2026, in the New England Journal of Medicine, divarasib, a new KRAS G12C pill, extended median survival to 17.7 months vs. 12.0 months with…